ERBB2 and breast cancer: Treatment of BT549 cells (TNBC), SK-BR-3 cells (HER2+ breast cancer), and SK-OV-3 cells (late stage, invasive ovarian cancer) with 200 μg/mL of BP1003 for 96 h resulted in a 30–40% decrease in STAT3 protein levels compared to cells treated with EL (Figure 1A).